n=202 A prospective, multicenter, single-blind study evaluating the safety and efficacy of DESyne BDS Plus. Study results: Achieved primary endpoint of TLF noninferiority No stent thrombosis (definite/probable), CVD, or TV-MI in the DESyne BDS Plus arm Sustained low TLF & TVF rates from 12 months to 24 months The post DESyne BDS Plus RCT appeared first on Elixir Medical .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules